



**Universiteit
Leiden**
The Netherlands

Integrating coronary atherosclerosis burden and progression with coronary artery disease risk factors to guide therapeutic decision making (vol 136, page 260, 2023)

Freeman, A.M.; Raman, S.V.; Aggarwal, M.; Maron, D.J.; Bhatt, D.L.; Parwani, P.; ... ; Shapiro, M.D.

Citation

Freeman, A. M., Raman, S. V., Aggarwal, M., Maron, D. J., Bhatt, D. L., Parwani, P., ... Shapiro, M. D. (2023). Integrating coronary atherosclerosis burden and progression with coronary artery disease risk factors to guide therapeutic decision making (vol 136, page 260, 2023). *American Journal Of Medicine*, 136(7), 720-721. doi:10.1016/j.amjmed.2023.03.021

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3729152>

Note: To cite this publication please use the final published version (if applicable).



Corrigendum to 'Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making' *The American Journal of Medicine* 136:03 (2023); 260-269.e7

Andrew M. Freeman, MD,^a Subha V. Raman, MD,^b Monica Aggarwal, MD,^c David J. Maron, MD,^d
Deepak L. Bhatt, MD, MPH, FACC,^e Purvi Parwani, MD,^f John Osborne, MD, PhD, FACC,^g James P. Earls, MD,^h
James K. Min, MD,^h Jeroen J. Bax, MD,ⁱ Michael D. Shapiro, DO^j

^aDivision of Cardiology, Department of Medicine, National Jewish Health, Denver, Colo; ^bDivision of Cardiology, Indiana University School of Medicine, Indianapolis; ^cDivision of Cardiovascular Medicine, University of Florida, Gainesville; ^dDepartment of Medicine, Stanford University School of Medicine, Stanford, Calif; ^eMount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY; ^fLoma Linda University Health, Loma Linda, Calif; ^gState of the Heart Cardiology, Dallas, Texas; ^hCleerly, Inc., New York, NY; ⁱLeiden University Medical Center, Leiden, Netherlands; ^jCenter for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC.

The authors regret that an error appeared in **Table 3**: Stage 1 should read "High-intensity statin: (Rosuvastatin 40mg QD/ Atorvastatin 80mg QD)". The corrected Table appears on the following page.

The authors would like to apologise for any inconvenience caused.

Table 3 Simplified approach to medical therapy based upon stage of atherosclerosis.

Stage	Treatment	Serial CCTA
Stage 0	<ul style="list-style-type: none"> • GDMT/Shared decision for de-escalation of therapy 	4 years
Stage 1	<ul style="list-style-type: none"> • High-intensity statin: (Rosuvastatin 40mg QD/Atorvastatin 80mg QD) • Ezetimibe 10mg QD 	3 years
Stage 2	<ul style="list-style-type: none"> • High-intensity statin (Rosuvastatin 40mg QD/Atorvastatin 80mg QD) • Ezetimibe 10mg QD • Aspirin 81 - 100mg QD • Rivaroxaban 2.5 mg BID <p><i>If diabetic, GLP1 receptor agonist</i></p>	2 years
Stage 3	<ul style="list-style-type: none"> • High-intensity statin (Rosuvastatin 40mg QD/Atorvastatin 80mg QD) • Ezetimibe 10mg QD • ASA 81-100mg QD* • Rivaroxaban 2.5mg BID* • Other Lipid lowering medications: PCSK-9 inhibitors, icosapent ethyl, inclisiran, bempedoic acid • Colchicine 0.6mg QD • Cardiac rehabilitation or other supervised exercise program (if covered) <p><i>If diabetic: GLP1 receptor agonist and SGLT2 inhibitor</i></p>	1 Year

Comprehensive atherosclerosis treatment algorithms for patients with lipid disorders, diabetes, hypertension, obesity and tobacco use can be seen in Supplementary Figures 1-4 (online).

*For patients at bleeding risk, use of rivaroxaban and aspirin is suggested only after shared decision making to ensure patient literacy of elevated bleeding risk.

ASA = acetylsalicylic acid; BID = twice a day; CCTA = coronary CT angiography; GDMT = guideline-directed medical therapy; GLP-1 = glucagonlike peptide 1; QD = once a day; SGLT2 = sodium-glucose transport protein 2